This brand name is authorized in Nigeria
The drug NEOSHAVE contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Methylprednisolone
UNII 43502P7F0P - METHYLPREDNISOLONE ACETATE
|
|
Methylprednisolone is a synthetic glucocorticoid and a methyl derivative of prednisolone. Methylprednisolone is a potent anti-inflammatory agent with the capacity to profoundly inhibit the immune system. |
|
2
Neomycin
UNII 057Y626693 - NEOMYCIN SULFATE
|
|
Neomycin is an aminoglycoside antibiotic and acts by binding to polysomes, inhibiting protein synthesis and generating errors in the transcription of the genetic code. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| D07CA02 | Methylprednisolone and antibiotics | D Dermatologicals → D07 Corticosteroids, dermatological preparations → D07C Corticosteroids, combinations with antibiotics → D07CA Corticosteroids, weak, combinations with antibiotics |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: NG | Registered Drug Product Database | Identifier(s): B4-9737 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
